Education
About Us
Working with TipRanks
Follow Us
Prestige Consumer Healthcare (PBH)
NYSE:PBH
PBH Stock Chart & Stats
$69.58
-$0.15(-0.20%)
At close: 4:00 PM EST
$69.58
-$0.15(-0.20%)
Day’s Range― - ―
52-Week Range$57.25 - $90.04
Previous CloseN/A
Volume57.25K
Average Volume (3M)456.76K
Market Cap
$3.15B
Enterprise Value$4.36B
Total Cash (Recent Filing)$62.37M
Total Debt (Recent Filing)$1.08B
Price to Earnings (P/E)18.2
Beta0.29
Next Earnings
Apr 30, 2026EPS Estimate
1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.14
Shares Outstanding47,318,730
10 Day Avg. Volume504,397
30 Day Avg. Volume456,760
Financial Highlights & Ratios
PEG Ratio7.62
Price to Book (P/B)2.33
Price to Sales (P/S)3.76
P/FCF Ratio17.56
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue3.95
Enterprise Value/Gross Profit7.01
Enterprise Value/Ebitda12.89
Forecast
1Y Price Target
$76.33Price Target Upside9.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Brand DiversificationA diversified portfolio of niche consumer healthcare brands tends to sustain sales across different consumer spending environments by retaining loyal shoppers for specific health needs.
Capital AllocationStable free cash flow and reasonable leverage provide flexibility to pursue accretive acquisitions, opportunistic share repurchases, and targeted debt reduction, supporting long-term shareholder returns.
Product MomentumMomentum in the gastrointestinal product line combined with several new product introductions is expected to raise demand across retail and e-commerce channels.
Bears Say
Guidance RiskManagement narrowed company guidance toward the low end of prior ranges, signaling a muted near-term outlook and leaving shares vulnerable without a clear catalyst.
Retail Channel DestockingInventory de-stocking in certain retail channels and lower retail orders have trimmed shipments and could delay a steady sales rebound.
Supply DisruptionsProduction disruptions for the Clear Eyes brand caused retailer stock shortages that directly reduced sales and eroded availability in the eye care category.
Prestige Consumer Healthcare News
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $57.25 and its highest was $90.04 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $3.15B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Apr 30, 2026 which is in 66 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Feb 05, 2026. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.145 by -$0.005.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of N/A. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 1.39.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,318,730 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $1.14 in its last earnings report, missing expectations of $1.145. Following the earnings report the stock price went down -2.208%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$76.33 (9.70% Upside)
$76.33 (9.70% Upside)
Blogger Sentiment
Bullish
PBH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 19.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $304.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.37%
12-Months-Change
Fundamentals
Return on Equity
11.29%
Trailing 12-Months
Asset Growth
3.78%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
PBH Company Deck
PBH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational and financial strengths — notably strong free cash flow (+~13% YTD), margin expansion (first nine months gross margin +50 bps and Q4 guide to ~57%), strategic acquisition (Pillar Five) to remedy long-standing Clear Eyes supply issues, and opportunistic buybacks — against persistent near-term headwinds driven by Clear Eyes supply constraints, category softness in analgesics/cough & cold/lice, a $10M supplier loan write-off, and volatile retailer ordering patterns. Management projects continued sequential supply improvements and maintained full-year free cash flow and narrowed EPS and revenue guidance, indicating confidence in financial resilience while acknowledging ongoing execution and demand uncertainties.View all PBH earnings summariesPBH Stock 12 Month Forecast
Average Price Target
$76.33
▲(9.70% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
McKesson
―
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
Currently, No data available
---